652 research outputs found

    Adjuvant S-1 chemotherapy after curative resection of gastric cancer

    Get PDF
    LETTER TO THE EDITOR: Authorā€™s replypublished_or_final_versio

    Zenker's Diverticulum: Can Protocolised Measurements with Barium SWALLOW Predict Severity and Treatment Outcomes? The "Zen-Rad" Study

    Get PDF
    Although barium swallow imaging is established in the investigation of Zenker's diverticulum (ZD), no agreed measurement protocol exists. We developed a protocol for measuring ZD dimensions and aimed to correlate measurements with symptoms and post-operative outcomes. This prospective study included patients with confirmed ZD who underwent flexible endoscopic septal division (FESD) between 2014 and 2018. ZD was confirmed on barium radiology with measurements reviewed by two consultant radiologists. Symptom severity pre- and post-FESD was measured using the Dysphagia, Regurgitation, Complications (DRC) scale. Regression analyses were conducted to identify dimensions associated with therapeutic success, defined as remission (DRC scoreā€‰ā‰¤ā€‰1) 6 months after index FESD. In total, 67 patients (mean age 74.3) were included. Interobserver reliability (intraclass correlation coefficients-ICCs) was greatest for pouch width (0.981) and pouch depth (0.934), but not oesophageal depth (0.018). Male gender (60.9%) was associated with larger pouch height (Pā€‰=ā€‰0.008) and width (Pā€‰=ā€‰0.004). A positive correlation was identified between baseline DRC score and pouch depth (Ļ 0.326, Pā€‰=ā€‰0.011), particularly the regurgitation subset score (Ļ 0.330, Pā€‰=ā€‰0.020). The index pouch depth was associated with FESD procedure time (rho 0.358, Pā€‰=ā€‰0.041). Therapeutic success was achieved in 64.2% and was associated with shorter pouch height (median 14.5Ā mm vs. 19.0Ā mm, Pā€‰=ā€‰0.030), pouch width (median 19.9Ā mm vs. 28.8Ā mm, Pā€‰=ā€‰0.34) and cricopharyngeal length (median 20.2Ā mm vs. 26.3Ā mm, Pā€‰=ā€‰0.036). ZD dimensions may be feasible and were evaluated using Barium radiology. Specific parameters appear to correlate with severity and post-FESD outcomes, which aid with pre-procedural planning

    Asymmetric Dimethylarginine, Endothelial Nitric Oxide Bioavailability and Mortality in Sepsis

    Get PDF
    Background: Plasma concentrations of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxidesynthase, are raised in patients with chronic vascular disease, causing increased cardiovascular risk and endothelialdysfunction, but the role of ADMA in acute inflammatory states is less well defined.Methods and Results: In a prospective longitudinal study in 67 patients with acute sepsis and 31 controls, digitalmicrovascular reactivity was measured by peripheral arterial tonometry and blood was collected at baseline and 2–4 dayslater. Plasma ADMA and L-arginine concentrations were determined by high performance liquid chromatography. Baselineplasma L-arginine: ADMA ratio was significantly lower in sepsis patients (median [IQR] 63 [45–103]) than in hospital controls(143 [123–166], p,0.0001) and correlated with microvascular reactivity (r = 0.34, R2 = 0.12, p = 0.02). Baseline plasma ADMAwas independently associated with 28-day mortality (Odds ratio [95% CI] for death in those in the highest quartile($0.66 mmol/L) = 20.8 [2.2–195.0], p = 0.008), and was independently correlated with severity of organ failure. Increase inADMA over time correlated with increase in organ failure and decrease in microvascular reactivity.Conclusions: Impaired endothelial and microvascular function due to decreased endothelial NO bioavailability is a potentialmechanism linking increased plasma ADMA with organ failure and death in sepsis

    Intraoperative ultrasound-guided iodine-125 seed implantation for unresectable pancreatic carcinoma

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>To assess the feasibility and efficacy of using <sup>125</sup>I seed implantation under intraoperative ultrasound guidance for unresectable pancreatic carcinoma.</p> <p>Methods</p> <p>Fourteen patients with pancreatic carcinoma that underwent laparotomy and considered unresectable were included in this study. Nine patients were pathologically diagnosed with Stage II disease, five patients with Stage III disease. Fourteen patients were treated with <sup>125</sup>I seed implantation guided by intraoperative ultrasound and received D<sub>90 </sub>of <sup>125</sup>I seeds ranging from 60 to 140 Gy with a median of 120 Gy. Five patients received an additional 35ā€“50 Gy from external beam radiotherapy after seed implantation and six patients received 2ā€“6 cycles of chemotherapy.</p> <p>Results</p> <p>87.5% (7/8) of patients received partial to complete pain relief. The response rate of tumor was 78.6%, One-, two-and three-year survival rates were 33.9% and 16.9%, 7.8%, with local control of disease achieved in 78.6% (11/14), and the median survival was 10 months (95% CI: 7.7ā€“12.3).</p> <p>Conclusion</p> <p>There were no deaths related to <sup>125</sup>I seed implant. In this preliminary investigation, <sup>125</sup>I seed implant provided excellent palliation of pain relief, local control and prolong the survival of patients with stage II and III disease to some extent.</p

    Eastern asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma

    Get PDF
    The largest burden of hepatocellular carcinoma (HCC) lies in Asia, secondary to hepatitis B virus (HBV) infection. Improved survival with sorafenib has fostered new research but many challenges remain in designing clinical trials. The disease, its management, and populations affected by it are heterogeneous worldwide and within Asia. An expert conference of Eastern Asian oncologists and hepatologists was convened to foster consensus in clinical trial design. The panel identified key areas that need to be addressed to facilitate clinical trials in Asia. Stratification by viral etiology is desirable within Asia and by region in global trials. Antiviral therapy should also be considered as a stratification factor and incorporated into HCC management in trials. The panel agreed that histological diagnosis is not required for trial entry and that Barcelona-Clinic Liver Cancer (BCLC) staging is acceptable for trials as long as portal hypertension can be better defined with standardized methodology. Consensus in treatment must be sought to allow multi-national trials and it must be recognized that first-line sorafenib is not largely feasible in Asia. Finally, Asian nations must be urged to participate in clinical trials, many of which are ongoing, to advance new treatment options in this challenging disease

    A new framework for sign language alphabet hand posture recognition using geometrical features through artificial neural network (part 1)

    Get PDF
    Hand pose tracking is essential in sign languages. An automatic recognition of performed hand signs facilitates a number of applications, especially for people with speech impairment to communication with normal people. This framework which is called ASLNN proposes a new hand posture recognition technique for the American sign language alphabet based on the neural network which works on the geometrical feature extraction of hands. A userā€™s hand is captured by a three-dimensional depth-based sensor camera; consequently, the hand is segmented according to the depth analysis features. The proposed system is called depth-based geometrical sign language recognition as named DGSLR. The DGSLR adopted in easier hand segmentation approach, which is further used in segmentation applications. The proposed geometrical feature extraction framework improves the accuracy of recognition due to unchangeable features against hand orientation compared to discrete cosine transform and moment invariant. The findings of the iterations demonstrate the combination of the extracted features resulted to improved accuracy rates. Then, an artificial neural network is used to drive desired outcomes. ASLNN is proficient to hand posture recognition and provides accuracy up to 96.78% which will be discussed on the additional paper of this authors in this journal

    Incidence of acute cerebrovascular events in patients with rheumatic or calcific mitral stenosis: a systematic review and meta-analysis

    Get PDF
    Background Patients with mitral stenosis (MS) may be predisposed to acute cerebrovascular events (ACE) and peripheral thromboembolic events (TEE). Concomitant atrial fibrillation (AF), mitral annular calcification (MAC) and rheumatic heart disease (RHD) are independent risk factors. Our aim was to evaluate the incidence of ACEs in MS patients and the implications of AF, MAC, and RHD on thromboembolic risks. Methods This systematic review was registered on PROSPERO (CRD42021291316). Six databases were searched from inception to 19th December 2021. The clinical outcomes were composite ACE, ischaemic stroke/transient ischaemic attack (TIA), and peripheral TEE. Results We included 16 and 9 papers, respectively, in our qualitative and quantitative analyses. The MS cohort with AF had the highest incidence of composite ACE (31.55%; 95%CI 3.60-85.03; I 2 =99%), followed by the MAC (14.85%; 95%CI 7.21-28.11; I 2 =98%), overall MS (8.30%; 95%CI 3.45-18.63; I 2 =96%) and rheumatic MS population (4.92%; 95%CI 3.53-6.83; I 2 =38%). Stroke/TIA were reported in 29.62% of the concomitant AF subgroup (95%CI 2.91-85.51; I 2 =99%) and in 7.11% of the overall MS patients (95%CI 1.91-23.16; I 2 =97%). However, the heterogeneity of the pooled incidence of clinical outcomes in all groups, except the rheumatic MS group, were substantial and significant. The logit-transformed proportion of composite ACE increased by 0.0141 (95% CI 0.0111-0.0171; p<0.01) per year of follow-up. Conclusion In the MS population, MAC and concomitant AF are risk factors for the development of ACE. The scarcity of data in our systematic review reflects the need for further studies to explore thromboembolic risks in all MS subtypes

    Fox-1 family of RNA-binding proteins

    Get PDF
    The Fox-1 family of RNA-binding proteins are evolutionarily conserved regulators of tissue-specific alternative splicing in metazoans. The Fox-1 family specifically recognizes the (U)GCAUG stretch in regulated exons or in flanking introns, and either promotes or represses target exons. Recent unbiased bioinformatics analyses of alternatively spliced exons and comparison of various vertebrate genomes identified the (U)GCAUG stretch as a highly conserved and widely distributed element enriched in intronic regions surrounding exons with altered inclusion in muscle, heart, and brain, consistent with specific expression of Fox-1 and Fox-2 in these tissues. Global identification of Fox-2 target RNAs in living cells revealed that many of the Fox-2 target genes themselves encode splicing regulators. Further systematic elucidation of target genes of the Fox-1 family and other splicing regulators in various tissues will lead to a comprehensive understanding of splicing regulatory networks
    • ā€¦
    corecore